A gene therapy mystery? GenSight blasted as 1st PhIII eye study ends in an intriguing failure
GenSight has a gene therapy mystery on its hands, which is about the last thing it wanted at the end of Phase III.
Assessing the 48-week data from its first pivotal test of a treatment for Leber Hereditary Optic Neuropathy — or LHON, a rare genetic disease that causes blindness — investigators pulled out a meaningful improvement in sight in their one treated eye.
The mystery: The other eyes that received a sham therapy did just as well with their eyesight. Exactly as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.